Evidence map›Paper›PMID 31907640›Full record

ArticleEJNMMI research2020

[

Elodie Jouberton, Sébastien Schmitt, Emmanuel Chautard, Aurélie Maisonial-Besset, Marie Roy, Nina Radosevic-Robin, Jean-Michel Chezal, Elisabeth Miot-Noirault, Yann Bouvet, Florent Cachin

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. UsingQuantitative imaging in medicine and surgery · 2025
    Article
  2. Article
  3. Review
  4. Interest and Limits of [Frontiers in oncology · 2021
    Review
  5. EJNMMI research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Elodie JoubertonService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France.
Sébastien SchmittUniversité Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
Emmanuel ChautardDépartement de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France.
Aurélie Maisonial-BessetUniversité Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
Marie RoyUniversité Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
Nina Radosevic-RobinDépartement de Pathologie, Centre Jean Perrin, Clermont-Ferrand, France.
Jean-Michel ChezalUniversité Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
Elisabeth Miot-NoiraultUniversité Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, UMR1240, Clermont-Ferrand, France.
Yann BouvetZionexa, Aubière, France.
Florent CachinService de Médecine Nucléaire, Centre Jean Perrin, Clermont-Ferrand, France. florent.cachin@clermont.unicancer.fr.ORCID http://orcid.org/0000-0003-2171-1496
Inserm · FR

Funding

Ligue Contre le Cancer 61200
6 · The paper itself

Abstract

purposePathological complete response to the neoadjuvant therapy (NAT) for triple negative breast cancer (TNBC) is predictive of prolonged patient survival. Methods for early evaluation of NAT efficiency are still needed, in order to rapidly adjust the therapeutic strategy in case of initial non-response. One option for this is molecular imaging of apoptosis induced by chemotherapy. Therefore, we investigated the capacity of [

resultsInitially, the induction of apoptosis by different therapies was quantified. We confirmed, in vitro, that paclitaxel or epirubicin, the fundamental cytotoxic drugs for breast cancer, induce apoptosis in TNBC cell lines. Exposure of TNBC models MDA-MB-231 and MDA-MB-468 to these drugs induced a significant increase (p < 0.01) of the apoptotic hallmarks: DNA fragmentation, membrane phospholipid scrambling, and PARP activation. Secondarily, apoptotic fraction was compared to the intracellular accumulation of the radiotracer. [

conclusionsThese results highlighted that PET imaging using [

Indexed as

[18F]ML-10apoptosischemotherapyin vivoPET imagingtriple negative breast cancer

Identifiers

PMID31907640
PMCPMC6944726
OpenAlexW3009825302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.